Hemispherx BioPharma Company Profile (NYSE:HEB)

About Hemispherx BioPharma (NYSE:HEB)

Hemispherx BioPharma logoHemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSE:HEB
  • CUSIP: N/A
  • Web: www.hemispherx.net/
  • Market Cap: $9.48 million
  • Outstanding Shares: 29,169,000
Average Prices:
  • 50 Day Moving Avg: $0.33
  • 200 Day Moving Avg: $0.47
  • 52 Week Range: $0.30 - $1.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.83
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $335,000.00
  • Price / Sales: 28.30
  • Book Value: $0.36 per share
  • Price / Book: 0.91
  • EBITDA: ($12,100,000.00)
  • Net Margins: -1,029.58%
  • Return on Equity: -75.57%
  • Return on Assets: -53.36%
  • Average Volume: 256,511 shs.
  • Short Ratio: 1.42

Frequently Asked Questions for Hemispherx BioPharma (NYSE:HEB)

What is Hemispherx BioPharma's stock symbol?

Hemispherx BioPharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "HEB."

How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSE:HEB) announced its earnings results on Monday, August, 14th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $0.21 million for the quarter. Hemispherx BioPharma had a negative return on equity of 75.57% and a negative net margin of 1,029.58%. View Hemispherx BioPharma's Earnings History.

Are investors shorting Hemispherx BioPharma?

Hemispherx BioPharma saw a increase in short interest in September. As of September 29th, there was short interest totalling 1,100,251 shares, an increase of 17.2% from the September 15th total of 938,792 shares. Based on an average trading volume of 263,493 shares, the short-interest ratio is presently 4.2 days. Currently, 4.0% of the shares of the stock are short sold.

Who are some of Hemispherx BioPharma's key competitors?

Who are Hemispherx BioPharma's key executives?

Hemispherx BioPharma's management team includes the folowing people:

  • William M. Mitchell, Chairman of the Board
  • Thomas K. Equels Esq., Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel
  • Adam Pascale CPA, Chief Financial Officer
  • Wayne Steven Springate, Senior Vice President - Operations
  • David R. Strayer M.D., Chief Scientific & Medical Officer
  • Peter W. Rodino III, Esq., Executive Director - Governmental Relations, General Counsel
  • Stewart L. Appelrouth, Director

How do I buy Hemispherx BioPharma stock?

Shares of Hemispherx BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hemispherx BioPharma's stock price today?

One share of Hemispherx BioPharma stock can currently be purchased for approximately $0.33.

MarketBeat Community Rating for Hemispherx BioPharma (NYSE HEB)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  41 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  78
MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Hemispherx BioPharma (NYSE:HEB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Hemispherx BioPharma (NYSE:HEB)
Price Target History for Hemispherx BioPharma (NYSE:HEB)
Analysts' Ratings History for Hemispherx BioPharma (NYSE:HEB)
No equities research coverage for this company has been tracked by MarketBeat.com


Earnings History for Hemispherx BioPharma (NYSE:HEB)
Earnings by Quarter for Hemispherx BioPharma (NYSE:HEB)
Earnings History by Quarter for Hemispherx BioPharma (NYSE HEB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2017Q2 2017($0.08)$0.21 millionViewN/AView Earnings Details
11/14/2016Q3 16($0.30)$0.02 millionViewN/AView Earnings Details
8/15/2016Q216($0.01)$0.02 millionViewN/AView Earnings Details
5/16/2016Q116($0.01)$40.99 million$0.04 millionViewN/AView Earnings Details
8/13/2015Q2($0.02)$0.05 millionViewN/AView Earnings Details
5/13/2015Q1 15($0.02)$0.04 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.03)ViewN/AView Earnings Details
11/5/2012Q312($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Hemispherx BioPharma (NYSE:HEB)
Current Year EPS Consensus Estimate: $0.000 EPS
Next Year EPS Consensus Estimate: $-0.030 EPS


Dividend History for Hemispherx BioPharma (NYSE:HEB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Hemispherx BioPharma (NYSE:HEB)
Insider Trades by Quarter for Hemispherx BioPharma (NYSE:HEB)
Insider Trades by Quarter for Hemispherx BioPharma (NYSE:HEB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/2/2017Adam PascaleCFOBuy15,873$0.63$9,999.99View SEC Filing  
5/2/2017David R StrayerInsiderBuy7,937$0.63$5,000.31View SEC Filing  
4/27/2017Thomas K EquelsCEOBuy72,464$0.69$50,000.16View SEC Filing  
4/11/2017Thomas K EquelsCEOBuy200,000$0.50$100,000.00View SEC Filing  
2/16/2017Adam PascaleCFOBuy6,981$0.46$3,211.26View SEC Filing  
2/16/2017David R StrayerInsiderBuy9,892$0.46$4,550.32View SEC Filing  
2/16/2017Wayne S SpringateSVPBuy8,014$0.46$3,686.44View SEC Filing  
12/22/2016Thomas K EquelsCEOBuy68,493$0.73$49,999.89View SEC Filing  
11/1/2016Thomas K EquelsCEOBuy10,000$1.00$10,000.00View SEC Filing  
7/8/2016Thomas K EquelsCEOBuy48,000$0.12$5,760.00View SEC Filing  
7/1/2016Thomas K EquelsCEOBuy171,000$0.12$20,520.00View SEC Filing  
3/18/2016Thomas K EquelsCEOBuy30,000$0.13$3,900.00View SEC Filing  
3/11/2016Thomas K EquelsCEOBuy40,000$0.16$6,400.00View SEC Filing  
3/10/2016Thomas K EquelsCEOBuy30,000$0.16$4,800.00View SEC Filing  
8/20/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/18/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/17/2015William A CarterCEOBuy25,000$0.18$4,500.00View SEC Filing  
8/14/2015Thomas K EquelsCFOBuy79,104$0.18$14,238.72View SEC Filing  
4/28/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/27/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/21/2015William A CarterCEOBuy100,000$0.24$24,000.00View SEC Filing  
4/20/2015Thomas K EquelsCFOBuy100,000$0.24$24,000.00View SEC Filing  
4/17/2015William A CarterCEOBuy73,681$0.23$16,946.63View SEC Filing  
4/16/2015William A CarterCEOBuy26,319$0.23$6,053.37View SEC Filing  
4/15/2015Thomas K EquelsCFOBuy100,000$0.23$23,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Hemispherx BioPharma (NYSE:HEB)
Latest Headlines for Hemispherx BioPharma (NYSE:HEB)
Loading headlines, please wait.



Hemispherx BioPharma (HEB) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.